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Biomarkers of cardiovascular riskPlasma high density lipoprotein cholesterol (HDL) comprises a heterogeneous family of lipoprotein species, dif-
fering in surface charge, size and lipid andprotein compositions.WhileHDL cholesterol (C)mass is a strong, grad-
ed and coherent biomarker of cardiovascular risk, genetic and clinical trial data suggest that the simple
measurement of HDL-C may not be causal in preventing atherosclerosis nor reﬂect HDL functionality. Indeed,
the measurement of HDL-C may be a biomarker of cardiovascular health. To assess the issue of HDL function as
a potential therapeutic target, robust and simple analytical methods are required. The complex pleiotropic effects
of HDL make the development of a single measurement challenging. Development of laboratory assays
that accurately HDL function must be developed validated and brought to high-throughput for clinical purposes.
This review discusses the limitations of current laboratory technologies for methods that separate and quantify
HDL and potential application to predict CVD,with an emphasis on emergent approaches as potential biomarkers
in clinical practice.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Plasma levels of high density lipoprotein cholesterol (HDL-C) are
strongly associated with atherosclerotic cardiovascular disease, espe-
cially coronary artery disease (CAD). This observation is strong, graded
and coherent across the populations studied [1]. In post-hoc analysis
of clinical trials, HDL-C remains a powerful predictor of residual risk,
even at low LDL-C levels [2]. In recent years, Mendelian randomization
experiments have casted doubt on the causal link between HDL-C and
CAD [3]. Furthermore, drugs that increase HDL-C, including ﬁbrates,
niacin and the cholesteryl ester transfer protein inhibitors torcetrapib
and dalcetrapib have failed to show improved cardiovascular outcomes.
One possible explanation to explain the discrepancy between the epide-
miological, genetic and clinical trial data is that themeasurement of the
cholesterol mass within HDL fails to capture the complexity of a highly
dynamic process [4,5]. HDL particles differ in size, ranging from 7 nm to
17 nm, shape (unfolded protein, discoidal and spherical), lipidome and
proteome [6,7]. The measurement of HDL-C has been standardized and
current precipitation techniques achieve a high degree of accuracy for
clinical purposes (Table 1). However, there is no accepted “gold stan-
dard” technique for the measurement of HDL particles. More reﬁned
techniques have been developed based on the physical and functional
properties of HDL (Tables 2, 3). In this review, we will address the tech-
niques of HDL measurement, determine whether the information pro-
vided ads to our ability to predict CVD, and evaluate the limitations of
these assays. The structural and composition (proteomic/lipidomic) of
HDL may provide further insights on its function [8,9]. HDL particles
possess many pleiotropic properties that are unrelated to their choles-
terol mass or the ability to transport it in the blood. These properties,
observed in vitro, may be a better metric to determine CVD risk. These
effects include HDL anti-inﬂammatory and anti-oxidant properties,
vascular endothelial cell, nitric oxide (NO) production, expressions of
inﬂammatory mediators, and endothelial progenitor cell proliferation
[5,10–13]. Further, the structure and composition analysis of HDL parti-
cles (proteomic/lipidomic), which provide additional insight into the
assessment of HDL particles with speciﬁc functions, are also discussed
(Tables 4, 5).
2. Controversy surrounding the relationship between HDL-
cholesterol measurement and CAD
Epidemiological studies have shown a consistent inverse association
between HDL-C concentration and CAD [1]. Clinical trials aimed at rais-
ing HDL-C pharmacologically have failed to show clinical beneﬁts in
terms of CAD reduction [14–17]. Moreover, Mendelian randomization
studies do not support a causal role for HDL-C in the pathogenesis of
CAD [3]. HDL-C level is a static measurement that likely represents a
biomarker of cardiovascular health, rather than a risk factor. Recent clin-
ical studies suggest that HDL-C is a helpful biomarker, but functional
testing, such as the cholesterol efﬂux capacity of HDL improves discrim-
ination, independently of HDL-C levels [18]. Despite the coherent epide-
miological data suggesting a cardioprotective role for HDL-C, the
antiatherogenic properties of different particles that constitute HDL
are highly heterogeneous and have yet to be fully quantiﬁed and theirroles properly evaluated. The cholesterol efﬂux capacity is likely more
reﬂective of a biologically relevant pathway in the prevention of athero-
sclerosis and CAD [18].
Thus, a newparadigm states thatweneed to determine andmeasure
the anti-atherogenic properties of HDL, rather than the cholesterolmass
within HDL. Other methods for measuring HDL function, reﬂecting
relevant causal pathways need to be established. Indeed, the cholesterol
content of HDL does not represent many biologically important HDL
properties that are relevant to CVD (Tables 2, 3). Methods for measure-
ment of HDL sub-fractions, as well as physiochemical (Table 2) and
functional (Table 3) may be more effective in predicting CAD risk than
HDL-C [19]. Thus, the concept that HDL-C does not necessarily reﬂect
HDL function, and that HDL function may be a better biomarker of
cardiovascular risk must be emphasized. Recently, various alternate
HDL phenotypes are being examined as surrogates for the beneﬁcial ac-
tions of HDL [5]. The functional heterogeneity of HDL particles makes
the identiﬁcation of effective clinical method to quantify HDL function
an ongoing challenge [5,20,21]. The pleiotropic HDL biological activities
(biomarker) have immediate relevance to understanding the keymech-
anisms implicated in the pathophysiology of atherosclerosis and throm-
bosis. Even though some HDL biomarkers, such as cholesterol efﬂux
capacity look promising, it is too early to embrace these measurements
in the clinical realm [22] (Table 5).
3. Methods of HDL measurement
In clinical practice, the standard measure of HDL is the cho-
lesterol content in HDL particles after precipitation of apoB-
containing lipoproteins (Table 1). More reﬁned techniques to de-
termine HDL-C in serum include ultracentrifugation (UTC) [23],
electrophoresis [24,25], high performance lipoprotein chromatog-
raphy (HPLC) [26,27], precipitation-based methods [28], direct
measuring methods [29,30], and nuclear magnetic resonance
(NMR) [31] (Table 2).
3.1. Precipitation methods for the separation of HDL
HDL-C is ﬁrst separated by precipitating apoB containing lipoproteins
from serum by using a combination of polyanions, typically such as hep-
arin–MnCl2, dextran sulfate–MgCl2 or phosphotungstate–MgCl2 [32,33],
and a divalent cation, such as magnesium, heparin–manganese, or calci-
um [34]. Subsequently, HDL is quantiﬁed as cholesterol in the supernatant
[35]. Polyethylene glycol (PEG) although not a polyanion is also used to
precipitate apoB-containing lipoproteins [36,37]. This method is a conve-
nient, reproducible, and rapid way to extract HDL from patient serum or
plasma [38]. Incomplete precipitation of apoB lipoproteins [35] is a
major drawback of this method [33,39]. Supernatant turbidity, observed
with hypertriglyceridemia, inﬂammatory conditions and cryopreserva-
tion [29,40,41] may lead to discordant results between methods [29,35,
42]. Commercial immunoprecipitation reagent using speciﬁc antibodies
directed against HDL particles could be effective in serum with elevated
triglycerides [33]. Because of speciﬁcity of anti-apoB antibodies, HDL par-
ticles will not co-precipitate with apoB, which may be an issue with
chemical precipitation methods [33]. Another limitation is that the
Table 2
Measurement of HDL by density and size.
The classic method for separation of lipoprotein subfractions is by density gradient
ultracentrifugation. Ultimately, more convenient methods such as preparative ultra-
centrifugation or short sequence steps based on ultracentrifugation were developed.
HDL subfractions can also be assessed based on size by ND-PAGGE or by charge and
size with 2D-PAGGE. Fast liquid chromatography or high liquid chromatography
(HPLC) is another method for classifying and quantifying lipoproteins according to
particle size. Nuclear magnetic resonance (NMR) spectroscopy is another rapidmeth-
od of assessing HDL subclasses that emits distinctive NMR signals arising from their
unique physical structure.
Separate HDL by ultracentrifugation Figure
UTC separation 1
• Flotational analytical ultracentrifugation [47,48]
• Sequential ultracentrifugation: isopycnic equilibrium method [23]
• Vertical auto proﬁle: zonal ultracentrifugation [51,53,54]
Separate HDL by charge
• Capillary isotachophoresis [82,83]
Separate HDL by size
Gel gradient electrophoresis separation
• Electrophoresis one dimensional gel electrophoresis [72,73] 2
• Electrophoresis 2D gel electrophoresis [6,74] 3
Fast liquid chromatography 4
• Ion exchange chromatography [63,64]
• Gel ﬁltration column [62]
Nuclear magnetic resonance 5
• Proton NMR measurement [31,92]
• Diffusion ordered NMR spectroscopy (DOSY NMR) [94]
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HDL-C measurement [43]. Precipitation methods are less expensive and
time consuming than ultracentrifugation [29]. PEG precipitation pre-
serves the integrity of pre-β HDL particles [37,44]. However, this tech-
nique can be contaminated with albumin, and thus unsuitable for
proteomic and lipidomic evaluation of HDL. Clinical data shows that
chemical based-precipitation methods could generate inaccurate HDL-C
results that were found to signiﬁcantly compromise the accurate classiﬁ-
cation of CAD risk [45]. Thus underlying the limitations of these methods
for measuring HDL-C [20,46].
3.2. Ultracentrifugation methods
3.3. Density gradient fractionation of plasma lipoproteins
Analytical UTC with density gradient ﬂotation using Schlieren op-
tics was used over 70 years ago to characterize lipoproteins [47]
(Table 2). With sequential ﬂotation, lipoproteins could be separated
into ﬁve major groups such as HDL, LDL, IDL, VLDL and chylomicrons.
In this multi-step process plasma based on the initial hydrated den-
sity range (1.006 g/mL) is increased to 1.063 g/mL with neutral salts,
such as NaBr or KBr [20,48]. Density gradient UTC approach is based
on the isopycnic equilibrium approach developed by Chapman et al.
[23] (Table 2). This method that uses a swinging-rotor, plasma or
serum is layered on the surface of a NaCl-KBr gradient, constructed
by consecutive layering of 4 salt solution distinct densities at
+15 °C. The process involves a single ultra-centrifugal step, facilitat-
ing HDL isolation in a nondenatured and nonoxidized state, and
avoids major contamination with the plasma proteins N1.25 g/mL
present at the bottom of the tube [20,49]. The density gradient UTC
method reduces centrifugation steps and preparation time [23] nec-
essary for isolating lipoprotein subspecies [50]. An important advan-
tage is that isopycnic UTC method allows isolating LDL subfractions
simultaneously with those of HDL.
3.4. Vertical auto proﬁle (VAP)
This assay, which involves a single vertical spin, is an inverted rate
zonal density gradient UTC technique that sequentially measures the
cholesterol content of all ﬁve lipoprotein classes [51,52] (Table 2). The
vertical rotor method or single vertical spin is a modiﬁcation of the
method for single spin separation and analysis of the major classes of
lipoproteins [51,53] described earlier. Unlike most other UTC methods,
the VAP method separates all lipoproteins in less than 1 h at
65,000 rpm [52,54,55]. This assay is sensitive (requiring b 50 μL of plas-
ma or serum) [48], economical and relatively widely available [20], and
provides a reasonable degree of accuracy [52]. VAP was validated in the
measurement of HDL2 andHDL3 [56], but limited studies have been per-
formed to compare this method to lipoprotein subfraction measure-
ment techniques, and show that NMR and ND-PAGGE agreed most
frequently and VAP had a lesser degree of correlation with these
methods [51].Table 1
Direct measurement of HDL-C mass by precipitation.
Plasma or serum HDL-C concentration is commonly determined by
precipitation methods using various reagents. Reagents involve
polyanions such as heparin, dextran sulfate, and sodium phospho-
tungstate,which are usedwith a divalent cation, such asmagnesium,
heparin–manganese, or calcium.
Precipitation
• Polyanions: heparin–Mn2+, dextran sulfate–Mg2+ [32]
• Divalent cation: dextran sulfate–Mg2+ [34]
• Polyethylene glycol [37,44,126,197]
• Immunoprecipitation [33]3.5. Limitations of UTC
Shear forces generated by the ultracentrifugal ﬁeld (57 × 107 g
average/min) may strip off proteins associated with lipoproteins;
these forces are reduced by the use of a swing rotor [48,54]. Another
biggest drawback of UTC lies in the fact that lipoproteins, especially
HDL particles are subjected to high ionic strengths 5 to 20 times above
those of human plasma and lymph [57,58]. These conditions can alter
the labile proteins on the HDL surface and cause minor structural
disruption to the HDL particles. Accordingly, a proteomic approach
showed that high salt can deplete the lipoproteins, especially HDL
[58]. Isopycnic gradient UTC procedures in a buffer of deuterium oxide
(D2O) and sucrose are suggested over salt [59]. Therefore, apolipopro-
teins, such as apoA-IV, can be signiﬁcantly overestimated by this meth-
od [59]. Earlier studies showed that the loss of apoA-I from HDL during
ultracentrifugal isolation is higher than other precipitation methods
[60] by as much as 50% [61]. However, the loss of apolipoproteins
from human HDL was not inﬂuenced by the effects of rotor conﬁgura-
tion, centrifuge tube type, ionic strength or temperature [57]. Further-
more, the plethora of different types of equipment used in laboratories
makes conditions extremely difﬁcult to reproduce, and separations are
highly dependent on the skills of the operator. While UTC is very useful
in research and has been considered as a “gold standard technique” [20]
for the separation of lipoproteins and HDL subpopulation, it is not
considered practical for routine analytical measurement (Table 5).3.6. High Performance Liquid Chromatography
HPLC is an analytical and preparative method for classifying and
quantifying lipoproteins according to size [62] (Table 2). In thismethod,
lipoproteins separated by permeation columns (exclusion chromatog-
raphy), the lipid components (mainly cholesterol and triglycerides)
are detected enzymatically. Various columns containing nonporous
polymer-based gels are used for separation of major classes of human
lipoproteins in serum and plasma [63]. For lipoprotein analysis, a
Superose 6 column is most frequently used [36,64–66]. Lipoprotein
separation using HPLC is divided broadly into two categories: HPLC
with a gel-ﬁltration column and HPLC with an anion-exchange column
(Table 2). Both methods can determine the lipid levels of fractionated
Table 3
HDL functional assay.
These tests exploreHDL pleiotropic effects as a biomarker of HDL function as themeasure-
ment of HDL–LCAT enzyme activity within the plasma compartment. Another test is
measurement of cholesterol efﬂux. RCT assays enable the measurement of cholesterol
from macrophages to feces. Non-radioactive assays aim to quantify lipid poor apoA-I or
cholesterol exchange to lipid poor apoA-I. Assays of antioxidant capacity of HDL involve:
inﬂammatory index andmonocyte chemotactic assay. Paraoxonase activity and HDL asso-
ciated myeloperoxidase in vitro assays. Assays for the endothelial effects of HDL on endo-
thelial NO and superoxide production and endothelial repair capacity were also discussed.
HDL–LCAT functional assay Figure
• LCAT mass: exogenous activity [65,66,119] 6
• LCAT fractional esteriﬁcation rate: endogenous activity [113,114] 7
Cholesterol efﬂux assays
• Measure of cholesterol efﬂux [130] 8
• Fluorescence efﬂux assay using BODIPY-cholesterol [137,138] 8
Non-radioactive assays for cholesterol exchange into lipid poor apoA-I 12
• Fluorescent apoA-I assay [198,199]
• TR-FRET version [140]
• Spin-label electron magnetic resonance [142]
Assays of HDL anti-inﬂammatory and functions of HDL
Assays of anti-inﬂammatory functions of HDL
• MCP1 production: inﬂammatory index [145,146,153] 13
• Monocyte chemotactic assay [144] 14
Assays of antioxidant functions of HDL
• Cell free assay [151–153] 15
• HDL associated PON1 assays [146,156,157] 16
• HDL associated MPO assays [12,141] 17
Vascular endothelial cell function and HDL
• NO [10,158,169–171] 18
• eNOS [13,168,172] 19
• ICAM/VCAM [13] 20
• Endothelial cell [13] 21
Table 4
Determination of HDL components (proteomics and lipidomics).
Formal proteomic analyses of HDL based on the recognition that HDL
containsmany proteins, which are performed by using variousMS tech-
niques. OnceHDL is puriﬁed, thewidermass spectrometric technologies
that have been employed to directlymapping theHDL proteome include
SELDI-TOF, MALDI-TOF, and ESI. Shut gun HDL lipidomic assays all used
MS and involve direct/indirect infusion approach. Direct infusion of
crude lipid extract into MS includes shotgun approaches: PSI-MS/MS,
ESI-MS/MS, and most recently MALDI (QIT)-TOF-MS/MS. Indirect infu-
sion assay separation of lipid species by LC–MS approaches uses two
different LC strategies, LC coupled to ESI-MS (LC–MS) or MALDI-MS.
Proteomic
Shut gun
• LC–MS/MS based MALDI-TOF [152]
• LC–MS/MS based SELDI-TOF [178]
Laser desorption ionization approaches
• LC–MS/MS ESI [200,201]
Lipidomic
Shotgun: direct infusion
• LC–ESI-MS [196]
• ESI-MS/MS [192,194]
Indirect infusion
• Maldi (QIT)-TOF-MS/MS [187,196]
• Triple quadrupole-MRM-MS [8,195]
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gel-ﬁltration HPLC method determines the lipid levels of lipoprotein
fractions by Gaussian approximation [67]. The HPLC method with an
anion-exchange column elutes lipoproteins based on the ion intensi-
ty of the lipoprotein particle surface and its hydrophobic properties,
and determines the cholesterol levels of separated lipoproteins
without overlapping lipoprotein fractions. This method provides
lipoprotein separation and larger-sized lipoproteins are eluted earli-
er (chylomicron, VLDL, IDL, LDL and HDL respectively). HPLC can be
contaminated by plasma proteins that co-elute with HDL, especially
albumin [26,68]. Anion-exchange HPLC has been used to character-
ize various dyslipidemias and the small instrument variation in
serum lipoprotein analysis conﬁrms its clinical utility [69]. The
rapidity of analysis and reproducible separation of lipoproteins [64]
makes HPLC reliable for cholesterol determination in lipoproteins
while not affecting lipoprotein composition [27,70]. HPLC is also
less tedious for large studies compared to UTC [57]. Combining
HPLC with UTC for the separation of HDL or LDL subfractions is
possible given the accuracy of HPLC [71]. This method was also
successfully applied to the analysis of the plasma lipoproteins of
patients with hyperlipidemia and showed more accuracy than
sequential UTC [63] (Table 5).
3.7. Non-denaturing polyacrylamide gradient gel electrophoresis
(ND-PAGGE)
ND-PAGGE was the ﬁrst method used for size-based separation of
lipoprotein subfractions (Table 2) that has been used as a standard
laboratory technique for the past three decades [48,72]. This technique
can identify various HDL subspecies separable on the basis of averagediameter into 6 distinct subclasses [73]. Patterns of apoA-I containing
HDL particles have been generated by ND-PAGGE and detected by
apoA-I western blot or radioimmunodetection of apoA-I [20,73]. Ac-
cordingly, a graphical representation of apoA-I containing HDL particles
in the plasma is shown in Fig. 1B. Although ND-PAGGE is considered a
sensitive and reproducible approach for quantifying the size distribu-
tion of HDL subpopulations in conjunction with automated density
[74,75], overall experience shows little additional beneﬁt when com-
pared with the more standard measurement of HDL-C [48]. Data for
pre-β1 and HDL2 species from this method showed a signiﬁcant linear
correlation [73] when associated with immunodetection method of
2D-PAGGE. However, thismethod is labor intensive and standardization
between laboratories is relatively poor, even when using commercially
available pre-cast gels, limiting its broad application [76].3.8. Two-dimensional gradient gel electrophoresis (2D-PAGGE)
2D-PAGGE is another technique used to separate HDL based on their
charge:mass ratio [74]. This method combines ND-PAGGE with agarose
gel electrophoresis, which used surface charge density in the ﬁrst
dimension and particle size in the second dimension. Most human
HDL particles in plasma are α-HDL observed as an α mobility by gel
electrophoresis, or preβ-HDL having preβ electrophoretic mobility by
gel electrophoresis [77]. Asztalos et al., by using antibodies to visualize
individual protein migration pattern in a native 2D-PAGGE, found
apoA-I in at least 11 distinct spots representing various species [74,
78]. Accordingly, a model of HDL subclasses was developed (Fig. 2).
Analogous to ND-PAGGE, this method is able to quantify HDL popula-
tions in conjunction with automated densitometry for further analysis
[75]. The two major HDL α-migrating species are usually described as
HDL3 (8.0 nm) andHDL2 (9.2 nm) [73]. HDL subclasses have various no-
menclatures, which depend on the HDL separation methods (Fig. 2). As
a result, a new HDL nomenclature and classiﬁcation based on size was
recently proposed [20]. The 2D-PAGGE analytical assay describes sever-
al novel variants of HDL (Table 5). 2D-PAGGE quantiﬁes preβ-1-HDL
[22,79,80], but this technique does not correlate precisely with sand-
wich ELISA designed and may overestimate preβ-1 concentrations in
plasma [81]. A variant of this method, using minigels and chemilumi-
nescence has been recently described [6].
Table 5
Summary.
Assays of HDL inhuman: advantages and limitations. The general principle and choice of isolation/fractionation procedure are listed. Effects and efﬁciencies of these various biomarkers are
presented.
Method Subfractions based separation Advantages Limitations
Precipitation ApoB depleted serum Cost, clinical applicability and high
throughput
Proteins and apoE fraction confounders in HDL supernatant
Density gradient UTC Particle density Gold standard for lipoprotein separation High ionic strength and centrifugal force, shear forces and salt
concentrations that may cause minimal structural disruption to the
particles
Single step UTC: VAP assay Particle density Fast and use from whole plasma just one
single predeﬁned, narrow density ranges
Some HDL individual subpopulations cannot be isolated
Gradient gel ND-PAGGE Size based separation Sensitive approach for quantifying the
size distribution of HDL subpopulations
— Non-preparative technique
— Unable to separate preβ-2 populations, and applied in specialized
laboratory (Fig. 1)
— A few data use this technique to study HDL subclasses in predicting
CVD
— Precast 4% to 30% or 3% to 30% gels are not commercially available or
are unreliable [73,74]
2D-PAGGE Surface charge and mass — Allows for the accurate diagnosis of
disorders of HDL metabolism
— Reproducible, standardized
— Provided information about CVD
— Consists of several variants in the protocol, and is applied in
specialized laboratory
— Provides little information on other HDL species as apoA-IV
Capillary isotachophoresis Electrophoretic based charge
separation
— Easy automation, one line monitoring
and rapid separation [202]
— Expensive, limited high-throughput analysis [86]
HPLC HDL particle size Rapid, accurate, reproducible separation
that does not affect lipoprotein
composition
— Applied more in specialized or clinical laboratories
— Albumin coelution with HDL fractions
NMR spectroscopy NMR signal of puriﬁed HDL — No prior sample manipulation
— Suitable for use in high-workload
— Efﬁciently quantiﬁes HDL and
lipoproteins
— Unable to provide HDL chemical compositional information
— All lipoprotein classes are not measured with the same degree of
accuracy
— It's not reported whether preβ-1 HDL subclass is detected
— Limited evidence for CVD risk prediction beyond HDL-C
Cholesterol efﬂux HDL cholesterol removing
capacity from plasma/serum
— Gold standard [125]
— Inversely associated with CAD and
carotid atherosclerosis [126,128]
— Represent only a small fraction of macrophage RCT
— Lack of standardization, and paradoxal association with CAD [132]
— Low throughput and not able to assess the terminal components of
the RCT pathway
LCAT assay Fractional esteriﬁcation rate Rapid, cost and reproducible — Require standardization and more larger studies are in need to
provide CVD prediction
— May not measure the initial esteriﬁcation rate and may not
reﬂect the turnover of cholesterol [113]
HDL inﬂammatory In vivo analysis of HDL to
suppress LDL-induced
chemotaxis
Explore HDL anti-inﬂammatory function Lack reproducibility and low throughput
HDL antioxidant Assay of HDL antioxidant
enzymes (PON1, MOP, cell free
assay)
Explore HDL anti-oxidation function Lack standardization and limited proof of concept
Endothelial assay — Generation of NO, eNOS
— ICAM/VCAM, MCP1, EPC
Quantify protective HDL endothelial
properties
Not available in routine
Proteomic HDL protein content Identify diversity of HDL proteins and
peptides
— Lack technical standardization, and need external validation
— Lack of coherence across analysis when compared to the same
clinical state
Lipidomic HDL lipid species content Identify diversity of HDL lipidome Limited by the available technologies
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Analytical free ﬂow capillary isotachophoresis (cITP) is a technique
that separates plasma lipoproteins into subfractions according to their
electrophoretic charge, and was originally developed by Bottcher et al.
[82] and Schmitz et al. [83]. Capillary isotachophoresis is based on the
speciﬁc staining of lipoproteins with the ﬂuorescent lipophilic dye be-
fore separation [83]. This method can separate plasma lipoproteins
into 3 major HDL subfractions (fast (f): onlyα-migrating HDL, interme-
diate (i): HDL particles rich in cholesterol, apoA-II, apoE and apoC, and
slow migrating (s) HDL: consisted of both α and preβ-migrating HDL)
according to their electrophoretic mobilities that can be determined as
peak areas relative to an internal marker [83]. Also, this technique can
separate charge based LDL subfractions in (fast, slow and minor) with
a drop of plasma and within minutes [84]. This technique is reported
in CAD clinical trial testing drugs that raise HDL-C levels [85,86], or in
evaluating mechanism of apoA-I mimetic peptides in plasma [87,88]
or also in some clinical laboratories as routine analytical assay [82]. Im-
portantly, in patient with hypercholesterolemia the charge-modiﬁedLDL subfraction as determined by cITP (fLDL) subfraction is
suggested as a possible potential useful biomarker for the risk of
CAD [89]. Moreover, in lipid lowering drug therapy, fLDL was effec-
tively reduced by low doses pravastatin and simvastatin [86]. More
studies are needed to demonstrate whether cITP (fLDL) is related
to clinical outcome and could be a target for therapy [90]. This
method is highly sensitive and only a very small amount of sample
is needed for the analysis. Unfortunately, the cITP technique has
limited potential of quantiﬁcation since the amount and ﬂuores-
cence yield of the dye incorporated into lipoproteins is likely to
vary with in-between lipoprotein subpopulations due to inter-
individual variations in their lipid content [89]. In addition the
cITP method determines not only the amount of total lipids but
also the composition (mass) of the individual lipoproteins [91].
However, evidence is still lacking because cITP technique is limited
in that the instruments for performing the cITP analysis are expen-
sive and not readily available. Moreover, high-throughput analysis
is limited by the nature of lipoproteins that they are susceptible to
modiﬁcation [86] (Table 5).
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Fig. 1. Separation of HDL-species by ND-PAGGE. The left panel (A) shows the apoA-I containing HDL subpopulations separated by ND-PAGGE (5–35%) of a normolipidemic, healthymale
subject (left) and healthy woman subject (right). Plasma samples were transferred to nitrocellulosemembrane, and probed by radiolabeled-I125 apoA-I radio imaging. Molecular markers
are indicated on the gel. Panel (B) is a schematic diagram of all the apoA-I containing α-HDL species.
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NMR employs the characteristic lipid methyl signal broadcast by
HDL subclasses whose individual amplitude can be accurately mea-
sured. This technique uses proton (1H, 13C and 32P) spectroscopy to
directly estimate the different sizes of lipoprotein subfractions rap-
idly [92]. NMR is widely used in specialty lipid reference laboratory
[31,92]. Using NMR, HDL has been classiﬁed into large (9.4–14 nm),
medium (8.2–9.4 nm) and small (7.3–8.2 nm) HDL subclasses17.0
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Fig. 2. Separation of HDL-species by 2D-PAGGE and techniques for measurement. Panel (A)
normolipidemic, healthy male subject. The plasma was subjected to 2-dimensional agarose
radiolabeled-I125 apoA-I. Molecular markers are indicated on the gel. Panel (B) is a schematic d
mined by different methods are shown: [1] ND-PAGGE and 2D-PAGGE (mass: charge); [2] UT
created by using the Autodesk 3ds Max 2014 software.(Fig. 2) [20,48,74]. Current NMR methods allow for the separation
of 26 subpopulations of HDL [9]. NMR analysis is precise for the
determination and quantiﬁcation of lipoprotein subclass [93]. Diffu-
sion ordered NMR spectroscopy (DOSY) that was recently is used for
the measurement of lipoprotein fractions to assess the risk of CVD
[94]. However, NMR based techniques use mathematical assump-
tions that do not take into account variations in the protein and
lipid cargoes of the particles [95] (Table 2). In addition, only a
modest correlation of selective NMR HDL measures has been foundHDL2
HDL3
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shows the apoA-I containing HDL subpopulations separated by 2D-PAGGE (3–24%) of a
/native PAGGE; samples were transferred to nitrocellulose membrane, and probed for
iagram of all the apoA-I containing HDL particles. Nomenclatures of HDL subclasses deter-
C (density) separation; and [3] NMR (size), [4] FPLC (size). The HDL particle images were
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uncertain [96]. Whether preβ-1 HDL is detected by NMR [22] has
not been reported. The most important limitation of this method is
the requirement for specialized equipment not found in routine
clinical laboratories.
4. HDL subclass measurement and CVD outcomes
Clinical and epidemiological studies have come to discordant con-
clusions on the prognostic value of HDL subclasses over the simplemea-
surement of HDL-C to predict CVD risk [2,13,16,47,95,97]. A key issue
has been the identiﬁcation of atheroprotective HDL. Multiple studies
showed that the levels of HDL2, as assessed by UTC or gradient gel elec-
trophoresis [24,25,72], are strongly associated with CHD independently
of HDL-C. Mounting evidence suggests that HDL3 particles may consti-
tute an equally valid measurement for assessing CVD risk [98–101].
Overall, UTC-based methods report that HDL2 and HDL3 subfractions
are independently related to CVD risk [102,103]. Conﬂicting results
between 2D-PAGGE and NMR for the prediction of CVD risk add to the
controversy [25,104]. Movva and Rader [48] attribute this discordance
to ethnic variation, different assaymethods used, or subfraction hetero-
geneity. Accumulating data using NMRmethods highlighted the impor-
tance of taking into account treatment status when considering risk
relationship of HDL species [94,97,105,106]. Plasma levels of preβ-1
lipoproteins were found to be signiﬁcantly higher in patients with
ischemic heart disease [107], and an independent predictor of CHD
beyond conventional risk factors [37,108]. HDL-preβ-1 subclass is not
found to be always atheroprotective [96,107,108]. Thus, considerable
controversy remains as to the clinical usefulness of HDL sub-species
for the prediction of CVD risk [109].
5. HDL functional assays
HDL function has become an area of interest, as descriptive tests of
HDL particles have provided only and sometimes marginal incremental
value over HDL-C measurement. This controversy has gained some
support in CETP deﬁcient subjects who, despite elevated HDL-C levels,
may not be protected from atherosclerosis [110]. The well described
apoAIMilano mutation appears to confer protection against atherosclero-
sis [111]. Despite extreme reduction in HDL-C, less than 50% of Tangier
patients develop CAD before age 40 [112]. Thus, a better understanding
of HDL functionality may shed light on the pleiotropic cardio-protective
effects of HDL.
5.1. Lecithin:cholesterol acyltransferase (LCAT) assay
LCAT mediates the esteriﬁcation of HDL cholesterol and favors
the maintenance of a gradient of free cholesterol between the plas-
ma membrane and HDL particles. An assay for endogenous LCAT
activity:fractional esteriﬁcation rate (FER) measures the esteriﬁca-
tion of radiolabeled free cholesterol that has been equilibrated
with HDL (Table 3) [113,114]. The FER is calculated as the ratio of
radioactive unesteriﬁed to radioactive esteriﬁed cholesterol per
unit of time and is expressed in (%/h) [115,116]. A variant of this
assay is based on the estimation of the radioactivity of free and
esteriﬁed cholesterol in plasma depleted of apoB [73]. Although
the FER reﬂects particle size distribution in HDL and LDL [48,113],
and is dependent on the metabolic milieu and distribution of lipo-
proteins [48]. The FER may not accurately reﬂect the turnover of
cholesterol since the preincubation and equilibration phases may
alter the substrate properties of the plasma and the radiolabeled
exogenous cholesterol may not be in complete equilibrium with
endogenous cholesterol [117]. The use of reconstituted HDL parti-
cles (proteoliposome) allows a more precise measure of LCAT
activity [118] (Table 3). Using reconstituted HDL, LCAT activity is
determined by the amount of cholesteryl ester (CE) incorporatedinto apoA-I-containing proteoliposomes, as a percent of CE divided by
total cholesterol [65,66]. This test correlated best with measures of LCAT
cholesterol esteriﬁcation rate [48,117]. The proteoliposome substrate
used in this assay is relatively easy to make and can be stored frozen for
a prolonged period of time, without loss of LCAT activation [119].
Calabresi et al. showed that defective LCAT activity does not result in
enhanced atherosclerosis, despite reduced HDL-C levels [120]. Adding to
the controversy, LCAT activity from patients undergoing angiography
was found to best predict the presence of coronary atherosclerotic lesions
[114]. These ﬁndings challenge the notion that LCAT is required for effec-
tive atheroprotection and suggest that increasing LCAT activity may not
be apromising strategy for reducing cardiovascular risk [121]. The contro-
versy of the association between LCAT activity and protection against
atherosclerosis remains [122,123].
5.2. HDL cholesterol efﬂux assay
HDL removes cholesterol from cells through ABCA1, including mac-
rophages, and this is considered to represent a major atheroprotective
function of HDL particles as shown in vivo [124]. In humans, differences
in macrophage-speciﬁc cholesterol efﬂux are predominantly due to
ABCA1-mediated cholesterol efﬂux, not to the other transporters [37].
Thus, examination of ABCA1 mediated cholesterol efﬂux is a plausible
target to quantify efﬂux capacity that could provide great relevance in
assessing the risk of atherosclerosis. The mechanisms involved in efﬂux
have attracted a great deal of investigation especially following the
recent neutral clinical study data of the Treatment of HDL to Reduce
the Incidence of Vascular Events (THRIVE) study [16]. Cholesterol efﬂux
is regulated by various intracellular transporters, such as ATP binding
cassette transporter proteins A1(ABCA1) and G1 (ABCG1) and scaven-
ger receptor type B1 (SR-B1). The radioactive assay of cellular cholester-
ol efﬂux that explores ABCA1 function is proposed as a “gold standard”
thatmeasures the efﬂux of cholesterol to lipid poor apoA-I [125]. ABCA1
uses apoA-I as the initial cholesterol acceptor and represents the rate-
limiting step in the reverse cholesterol transport pathway [99,
126–129]. The cellular cholesterol efﬂux assay aims to quantify the
rate of cholesterol efﬂux from cultured cells to an acceptor particle or
to plasma (Table 3). Many variations exist and attempts are made to
standardize this assay, by posting protocol on-line [130]. Protocols differ
by the type of cell, acceptormilieu, efﬂux times, and the speciﬁcity of the
transporter examined [96,116,126,129]. Brieﬂy, cholesterol efﬂux is cal-
culated as the percentage of the cellular (3[H] or 14[C])-cholesterol that
appears in the media onto an acceptor per unit of time [131]. A link
between the in vitro efﬂux of cholesterol frommacrophages and athero-
sclerosis has recently been established by clinical studies demonstrating
a negative correlation between cholesterol efﬂux from J774mouse cells
and coronary artery disease (CAD) or carotid atherosclerosis indepen-
dently of HDL-C mass [18,126,128,129]. It remains to be determined if
the HDL cholesterol efﬂux measurement correlates with clinical out-
comes [132,133]. A recent population-based cohort established inverse
association between efﬂux capacity and the incidence of CAD that
persisted after adjustment for traditional risk factors, HDL-C levels and
HDL particle concentration [18]; these data should inﬂuence future
study designs of HDL-modifying drugs.
In fact, the association between enhanced efﬂux and increase in the
incidence of CVD is still fueling discussions as to the pertinence of this
biomarker of HDL function. Regardless of the cellular model, it must
be emphasized that the use of apoB-depleted serumneglects the contri-
bution of apoB lipoproteins to the cholesterol efﬂux capacity [134].
Moreover, macrophages can efﬂux cholesterol not only onto lipid free
apoA-I, but also to apoE, and onto nascent HDL particles via the ABCA1
transporter, or onto mature spherical HDL particles via the ABCG1 or
SR-BI transporters. These confounders could strongly inﬂuence choles-
terol efﬂux capacity of serum independently of HDL composition and
functionality. However, it seems paradoxical that lipid free apoA-I
would play a similar role in vivo, because lipid free apoA-I state is not
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Fig. 3. Schematic representation of HDL functional assays in RCT pathway. Hepatocytes, enterocytes andmacrophages express ATP-binding cassette (ABC) transporter A1 (ABCA1), which
efﬂuxes phospholipids and cholesterol (assay 8) and thereby lipidates apoA-I extracellularly (assays 2–3). Efﬂuxed (FC) ismodiﬁed by theHDL enzyme (LCAT) into (CE) (assays 6–7). The
initially smaller HDL3 (assays 1–2–3–4–5) particles grow in size by ongoing lipid efﬂux, and cholesterol esteriﬁcation. The resulting HDL2 (assays 1–2–3–4–5) particles deliver lipids to the
liver, either directly via SR-BI and indirectly via CETPmediated transfer of CE to VLDL and LDL (assays 1–4–5). The RCT is ﬁnalized by the biliary excretion of cholesterol from the liver into
the intestine either directly via ABCG5 and ABCG8 to bile acids via the bile salt export pump ABCB11 (assays 10–11). The actions of hepatic lipase (HL), and endothelial lipase (EL) onHDL3,
aswell as of PLTP on HDL2, liberate lipid-free apoA-I (assays 2–3). Lipid free apoA-I is either used for de novo formation ofmatureHDL particles or isﬁltrated through the renal glomerulus
for tubular uptake and degradation (dotted arrows). Numbers in rectangles refer to Tables 2,3.
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tion is that lipid free apoA-I, generated in vivo through an apoA-I
remodeling cycle is rapidly lipidated by ABCA1, or may be incorporated
in preexisting plasma HDL [135]. It follows, that the ex-vivo cell-based
efﬂux system may highly reﬂect total in vivo macrophage cholesterol
efﬂux, and is quite useful for examining the ﬁrst step in the RCT path-
way [79,135,136] (Fig. 3). However, this approach does not lend itself
easily to the development of a high-throughput assay that can efﬁcient-
ly screen large numbers of specimens [137].
Unfortunately, the cholesterol efﬂux assay has a low throughput as it
employs 3[H] cholesterol, has poor dynamic range, fails to measure
phospholipid efﬂux by ABCA1, ignores measurement of hepatic HDL
formation and includes limited data linking efﬂux capacity to coronary
disease (Table 5) [137]. To avoid the use of radioisotopes, a ﬂuorescent
boron dipyrromethene diﬂuoride cholesterol probe (BODIPY-cholester-
ol) was used as alternative to label cholesterol [137,138]. This method
showed moderate correlation (0.54) with measurement performed
with radiolabeled cholesterol efﬂux [18]. Although this method pro-
vides efﬁcient measurement of efﬂux when compared with the use of
radiolabeled cholesterol, it still requires labeling of cellular sterols [139].
5.3. Non-radioactive assays for cholesterol exchange onto lipid poor apoA-I
These approaches focused on the conformational change in apoA-I
protein in HDL biogenesis and remodeling. These techniques quantify
HDL-apoA-I exchange between lipid associated and lipid free states,using time-resolved ﬂuorescence resonance energy transfer (TR-FRET)
or a discontinuous assay that uses the label-free Epic platform [140].
The TR-FRET assay employs HiLyte Fluor 647-labeled apoA-I with
N-terminal biotin bound to streptavidin-terbium. When ﬂuorescent
apoA-I was incorporated into HDL, TR-FRET decreased proportionally
to the increase in the ratio of lipids to apoA-I. In the Epic assay, biotinyl-
ated apoA-I was captured on a streptavidin-coated biosensor. Measured
resonant wavelength shift was proportional to the amount of lipids as-
sociated with apoA-I, indicating that the assay senses apoA-I lipidation
[140]. However, potential background ﬂorescence emission was
observed when using ﬂuorescent probe [140,141]. The main disadvan-
tage is that this assay appears to be less sensitive than the approach
using FRET [140]. Moreover, the inherent ﬂuorescence of blood plasma
and serum limits the clinical utility of this approach to quantifying HDL-
apoA-I exchange [140,141]. A new assay that employs a site-directed
spin-label electron paramagnetic resonance was recently described
[142], or by sensing hydrophobicity change in POLARIC-labeled apoA-I
[139]. These techniques show promise but remain to be validated in
large population-based or clinical study samples.
5.4. HDL anti-inﬂammatory assay
The use of proteomics to probe the complex heterogeneity of HDL
has helped uncover over 200 different proteins that reside on HDL
particles. Of these, more than two dozens are related to the immune
response [143] (Table 3). The anti-inﬂammatory properties of HDL
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techniques. The monocyte chemotaxis assay assesses the ability of
HDL to inhibit LDL oxidation and monocyte chemoattractant protein 1
(MCP1) expression through the HDL inﬂammatory index in the pres-
ence or absence of HDL [144–146]. A new approach for quantifying
the anti-inﬂammatory response to HDL involves measuring the cyto-
kine response in lipopolysaccharide-activated macrophages [133,147].
Some studies suggest that the HDL-inﬂammatory index may constitute
an improved biomarker in assessing CVD risk overHDL-C levels [38,145,
148]. The limited reproducibility of these assays casts doubt on their
clinical utility. HDL also suppresses in vitro type I interferon response
of macrophages induced by lipopolysaccharide [149]. To date, there
has been limited application of these assays outside the research
laboratory.
5.5. HDL antioxidant capacity assay
HDL particles contain several enzymes, including phospholipase A2,
glutathione peroxidase, paraoxonase-1 (PON1) and myeloperoxidase
(MPO) [5,11,20,150]. These enzymes prevent or break down oxidized
phospholipids, which prevent the formation of oxidized LDL particles
[12,98,146]. Assays of HDL oxidation that are discussed include a variety
of speciﬁc assays (Table 4).
1) Cell free assays of HDL oxidation. The cell-free assay examines the
effect of HDL on the production of reactive oxygen species after
oxidation and conversion of dichlorodihydroﬂuorescein diacetate
(DCF-DA) to ﬂuorescent signal DCF (2′,7′-dichloroﬂuorescein)
[151]. Direct measurement of ROS after exposure to HDL is reﬂected
by the increased DCF ﬂuorescence, which in turn reﬂects the oxida-
tive properties of different types of HDL particles that vary in their
capacity to engage intrinsic redox cycling [151]. Although this
assay yielded data that correlated with a cell-based assay [151,
152], its use is limited by the short shelf life of DCF-DA and interfer-
ence related to the assay's sensitivity to hemolysis and the presence
of metal chelators [22]. A new ﬂuorometric method based on the
oxidation of dihydrorhodamine 123 (DHR) by HDL was developed
[153]. This test assesses the intrinsic ability of HDL to be oxidized
by measuring increasing ﬂuorescence due to DHR oxidation over
time. Based on this, the HDL oxidant/antioxidant index was used as
the rate of DHRor rhodamine oxidation [154]. The direct comparison
of this measurement correlated well with the results obtained by
using a validated cell-based assay [152,153]. However, this assay
needs validation to large-scale clinical studies.
2) Paraoxonase (PON1) measurement. PON1 activity can be mea-
sured by spectrophotometric methods that can be automated
[155]. Serum arylesterase and paraoxonase activities are inde-
pendently measured respectively by UV spectrophotometry
using phenyl acetate (at 270 nm) or paraoxon (at 405 nm)
as substrates [156]. Most assays are based on monitoring p-
nitrophenol formation from the substrate paraoxon using phe-
nyl acetate or paraoxon as substrates [157]. This assay is based
on the chemiluminescence emitted by dichloroﬂuorescein that
quantiﬁes the antioxidation activity of HDL. Increasing evidence
from both animal and human studies links low PON1 activity
(but increased PON1 mass) to the increased likelihood of CVD
[158,159]. A PON1 activity method measurement has been pro-
posed [146] as a biomarker of HDL functionality in experimental
models and in therapeutic interventions in humans (Table 3).
However, the correlation of PON1 activity with HDL-C levels in
plasma is controversial [160]. Furthermore, PON1 activity was
used in apoA-I mimetic drug studies as an indicator of the
improvement of HDL antioxidant properties [153]. This enzyme
is a promised biomarker of HDL function and cardiovascular risk
independently of HDL-C levels. However, various factors should
be considered when estimating PON1 activity, including itscardioprotective properties, as well as age, gender, lifestyle,
medical conditions and pharmacological agent [161].
3) Myeloperoxidase (MPO) activity measurement. MPO-mediated oxi-
dation is proposed for measuring HDL oxidation (Table 3). Two MPO
oxidation products, 3-chlorotyrosine and 3-nitrotyrosine, are quanti-
ﬁed by tandem mass spectrometry in plasma and HDL [12]. By using
this approach, phagocyte-derived MPO oxidation products might be
useful indicators of the risk of CVD [162].MPOactivity can be analyzed
bymeasuringMPOmass in plasmawith an automated chemilumines-
centmicroparticle immunoassay [118]. Recent data showed that both
MPO and PON1 interact at the same site on HDL, which inﬂuences
oxidant stress and lipid peroxidation during inﬂammation [11,163].
Data among subjects with CVD shows that increased MPO activity
was associated with a decrease in HDL functional measures [164]. In
this context it is relevant that plasmaMPO is elevated in ACS patients
[118]. Increasing evidence suggests that MPO is causally linked to
atherosclerosis and its measurement may improve CVD risk estima-
tion [141,150]. Recent studies highlighted the utility of the MPO
assay as a biomarker of CVD risk in patients with systemic inﬂamma-
tion [164,165]. Whether oxidized HDL-proteins by MPO activity are a
goodmarker of dysfunctional HDL and CVD risk remain to be validat-
ed in large-scale studies.5.6. Vascular endothelial eNOS assay
HDL particles and HDL-derived cholesterol have been shown to
increase the expression and stability of nitric oxide synthase (eNOS)
in vascular endothelial cells (Table 3). These properties of HDL can be
examined by measuring NO production by ﬂuorescence in cell culture
systems [166]. HDL effects on eNOS activation can be measured by
quantifying the ratio of ser1177/thr495 phosphorylation [166–168].
Data from this assay have consistently demonstrated the ability of
HDL to modulate eNOS expression and NO production [10,11,158]. An
automated method to measure NO production, peripheral tonometry
(Endo-PAT), is available [169]. A close correlation exists between the
Endo-PAT method and assay of HDL mediated eNOS phosphorylation
in healthy children [167]. The validity of this approach is critically
dependent on the timing of the measurement as NO dissipates rapidly
[169]. Another approach is to measure brachial artery ﬂow-mediated
dilatation by using B-mode carotid ultrasound [170,171]. A test based
on electron spin resonance spectroscopy showed a reduced ability of
HDL to stimulate endothelial NO production in patients with advanced
CHD [13,172]. This measure is difﬁcult to apply routinely in the clinic
because it is subject to high individual variation. The assessment of
the endothelial function in the clinic is limited by the complex analytical
methods and a high degree of inter- and intra-individual variability.
5.7. Endothelial ICAM/VCAM assay
The expression of intercellular adhesion molecules (ICAMs) and
vascular cell adhesion molecule-1 (VCAM-1) that forms vascular endo-
thelial cell in response to an inﬂammatory stimulus (via nuclear factor
κB— NF-κB) can be modulated by HDL [13,173] (Table 3). The peptides
can be measured in plasma by ELISA or gel separation techniques [13,
168] and provide a biomarker of vascular inﬂammatory state. The effect
of HDL on endothelial progenitor cells (EPC) had been examined in an
in-vivo system of carotid denudation in the athymic nude mouse. In
this system, injured (electrical endothelial denudation) carotid arteries
are examined for EPC-mediated endothelial repair (Fig. 4) [174,175].
The re-endothelialized area can be measured by computer-assisted
morphometric analysis. This model has been shown to allow accurate
quantiﬁcation of re-endothelialization [13]. Clinical studies using this
method have shown the restoration of endothelial-protective proper-
ties of HDL in patient with 2 diabetes mellitus under extended-release
niacin therapy [13]. This is a fertile area of research of the biological
Fig. 4.Mechanisms of vascular effects of normal HDL and associated functional assays. Circulating monocytes attach to endothelial cells by cell adhesion molecules (assay 20) that are
induced in response to inﬂammatory signals, which is facilitated by endothelial adhesion molecules, including ICAM1/VCAM1 (assay 20). HDL causes membrane-initiated signaling,
which stimulates eNOS activity (assay 19). Monocytesmigrate through the endothelial layer into the intima, where they differentiate further intomacrophages in response to locally pro-
duced factors such asmonocyte colony-stimulating factor (assays 13–14). The recruitedmonocytes differentiate intomacrophages or dendritic cells in the intima,where they interactwith
atherogenic lipoproteins (LDL) (assay 13). LDL penetrates into the artery wall where it can adhere to proteoglycans. These interactions are thought to trap the LDL particles and increase
their susceptibility to oxidation. Enzymes contributing to LDL oxidation include lipoxygenases, MPO and eNOS that induce NO release in the endothelium (assays 17, 18, 19). HDL-asso-
ciated PON1 (assay 16) inhibits macrophage cholesterol biosynthesis and enhances HDL-mediated cholesterol efﬂux. Numbers in rectangles refer to Table 3.
Figure inspired and modiﬁed from Bessler et al.
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potential biomarkers of HDL function.
6. Proteomic analysis
Nearly 200 putative proteins have been identiﬁed in the HDL prote-
ome, and more than half have been independently conﬁrmed in sepa-
rate laboratories [176]. Many proteins appear functionally associated
with anti-inﬂammatory, antioxidant or anti-atherogenic properties of
HDL [152,177], suggesting that the HDL proteome offers a biomarker
of HDL dysfunction in CVD or ACS due to oxidative stress [44,173,
178–180] (Tables 4, 5). Several techniques are used, including shotgun
proteomics. In this approach, HDL proteins are ﬁrst separated by elec-
trophoresis, digested into peptides, and further separated by liquid
chromatography and quantiﬁed by tandem mass spectrophotometry
MS (LC–MS/MS) (Table 4). This method used electrospray ionization
(ESI) [179]. LC–ESI-MS/MS is highly sensitive for the resolution of
small peptides (6–20 amino acids long), down to the nano and picomole
ranges [178,181] showing additional protein group in HDL particles
from patient with CHD [152,172]. An additional beneﬁt of ESI is the
ability to use lower ﬂow rates (3–6 μL/min) for faster evaporation
time and longer measurement time. The LC–ESI-MS/MS has been the
most frequently used technique when compared to other MS
approaches, such as MALDI-TOF [44,152,177,182,183]. HDL shotgun
proteomic analysis [22] is limited by its semi-quantitative nature, the
dependence of the results on the MS technology used and the nature
of the initial biological material (serum, plasma, or biologic extract). A
degree of variation has been reported across studies with regard to
the number and the identity of the proteins associated with HDL
[176]. This is likely due to technical differences, experimental design
and diagnostic relevance of the biomarker identiﬁed, which highlights
the need for methodology standardization and external validation
[184]. HDL proteomic studies are in an early stage of development and
general conclusions about the HDL proteome as a biomarker for CVD
are limited by the small number of published studies.7. HDL lipidome assays
Recently, lipidomic approaches have provided insights into the
HDL lipidome with identiﬁcation of more than 200 individual mo-
lecular lipid species in HDL [9,185]. Various approaches for the
characterization of individual molecular species are discussed
above (Table 4).
With the development of tandem MS, the analysis ability of MS
has greatly improved by using analyzers including quadrupole
time-of-ﬂight (QqTOF) [44,186,187], or triple quadrupole instru-
ment [101,188] (Table 4). One of these applications is the ESI MS
shotgun lipidomics [189]. Ionization technology ESI was showed
to be more convenient for polar lipids and some other less-polar
lipids [190,191]. Shotgun ESI-MS/MS offer advantages, especially
in terms of sample throughput, untargeted analysis and coverage
of a broad spectrum of lipid species [192]. However the main draw-
backs of direct infusion are potential low resolution [193]. For more
accurate measurement, the HPLC separation before ESI-MS was
introduced [192]. On the other hand, there are several detection
modes in the triple quadrupole MS, precursor ion scan (PIN),
neutral loss scan (NLS) [194] and multi-reaction monitor (MRM)
[8]. The MRM approach demonstrates that 312 lipids could bemon-
itored in 20 min [195]. Instrumental robustness, speed of analysis
and sensitivities make targeted approaches more promising for
high throughput lipid analysis of complex biological samples
[196] (Tables 4, 5).
8. Summary and perspectives
Various methodologies have been developed for isolation of HDL
subfractions, without establishing uniform characterization of the
subfraction of HDL (Table 5). The potential of “omics” approaches may
provide additional insight into the assessment of HDL particles with
speciﬁc functions, and might be important in unraveling the controver-
sies surroundingHDL-based therapies. This reviewhighlights the lack of
185A. Haﬁane, J. Genest / BBA Clinical 3 (2015) 175–188agreement between methods, especially with specimens from patient
with CVD. Each technique of HDL quantiﬁcation raises inherent incom-
patibilities in the nomenclature of the separated HDL subclasses (Fig. 2).
It is critical to develop new metrics to determine whether HDL is
cardioprotective in humans. Attempts to harmonize the deﬁnition of
HDL are an important ﬁrst step [20]. Providing better biomarkers of
HDL function would be important in understanding the current clinical
equipoise and the neutrality of clinical beneﬁt for many HDL-C raising
therapies.
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